Hikal Ltd Share Price Today

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 20% at ₹0.4/Share	04-Sep-2026	04-Sep-2026
DividendsInterim Dividend of 10% at ₹0.2/Share	17-Feb-2026	17-Feb-2026
DividendsFinal Dividend of 40% at ₹0.8/Share	02-Sep-2025	02-Sep-2025
DividendsInterim Dividend of 30% at ₹0.6/Share	07-Feb-2025	07-Feb-2025

Mutual Fund Holder	Jul 26 Shares held	Aug 26 Shares held
ICICI Prudential Healthcare Fund - Growth	-	36.41 Lac (100%)
Tata Small Cap Fund - Regular Plan - Growth	33.00 Lac	33.00 Lac no change
Motilal Oswal BSE Healthcare ETF	1.01 k	1.01 k (0.2%)
Bandhan BSE Healthcare Index Fund - Regular Plan - Growth	544	477 (12.32%)
Motilal Oswal BSE 1000 Index Fund - Regular Plan - Growth	110	110 no change

Mayank Kumar

7 Sep • 3:32 PM · SEBI-Registered Analyst

Hikal is showing signs of a gradual recovery

HIKAL

Hikal is showing signs of a gradual recovery, but the turnaround is still incomplete. In Q1 FY27, consolidated revenue increased 5.9% YoY to ₹402.8 crore, while EBITDA rose sharply 49% to ₹36.6 crore, with EBITDA margin improving to around 9% from 6.5%. However, the company still reported a net loss of ₹7.4 crore, although this was significantly lower than the ₹22.4 crore loss in Q1 FY26. The key positive is the Pharmaceutical segment, where revenue grew 15.2% to ₹233 crore, supported by better customer offtake, differentiated APIs and CDMO opportunities. Hikal is also increasing its DMF filing pace and has commissioned a new cGMP pilot plant in Pune. On the other hand, the Crop Protection business remains under pressure because of customer inventory adjustments, pricing pressure and higher input costs, particularly due to geopolitical disruptions.

Adarsh Nimborkar (SEBI IA)

3 Sep • 12:36 PM · SEBI-Registered Analyst

Hikal Ltd – Company Fundamental Analysis

HIKAL

Hikal is a life-sciences contract development and manufacturing company operating across Pharmaceuticals and Crop Protection, with capabilities spanning APIs, intermediates, CDMO and complex chemistry. The business has been going through a difficult phase due to regulatory issues in Pharma and prolonged pricing pressure/inventory correction in Crop Protection. FY26 revenue declined around 8% to ₹1,713 crore, while EBITDA fell 30% to ₹233 crore. The company reported a ₹49 crore consolidated loss, partly aggravated by exceptional charges, including impairment and labour-code related costs. There are, however, signs of operational recovery. In Q1 FY27, revenue increased 5.9% YoY to ₹403 crore and EBITDA improved sharply to ₹37 crore from ₹25 crore, taking the EBITDA margin to 9.2%. Pharma revenue grew 15.2% and the segment returned to profitability at the operating level, while Crop Protection remained weak with a 4.7% revenue decline and segment-level loss. Hikal is also increasing DMF filings to 5–6 annually, expanding differentiated APIs/CDMO capabilities and has commissioned a new cGMP pilot plant in Pune. The investment case is therefore more of a turnaround opportunity than a proven growth story. Recovery in Pharma, normalization of Crop Protection demand, higher-value API/CDMO products and China+1 outsourcing could drive meaningful earnings improvement. On the other hand, the USFDA-related issues, competitive pricing, raw-material inflation, subdued CDMO demand and relatively weak current profitability remain important risks. Overall, Hikal has attractive technical capabilities and a potentially improving business cycle, but I would want to see sustained margin expansion and a return to consistent profitability before treating it as a strong long-term compounder.

Prameela Balakkala

6 Aug • 3:34 PM · SEBI-Registered Analyst

Hikal Q1: Loss Narrows, Margins Expand

📊 Q1 FY26 Results Snapshot Net Loss: ₹74M vs ₹224M (YoY) ⬇️ Revenue: ₹4B vs ₹3.8B (YoY) ⬆️ 5% EBITDA: ₹370M vs ₹251M (YoY) ⬆️ 47% EBITDA Margin: 9.2% vs 6.6% (YoY) ⬆️ 2.6 pp 📌 Fundamentals & Ratios (FY25 Snapshot) Revenue: ~₹15.5B Net Loss: ~₹0.6B (FY25) Debt-to-Equity: ~0.7 (moderate leverage) P/E Ratio: Negative (loss-making) ROE: Negative (losses weigh on returns) Dividend Yield: Nil (no payouts due to losses) 🏦 Business Drivers & Projects Pharma APIs: Growth in active pharmaceutical ingredients. Crop Protection Chemicals: Expanding agrochemicals portfolio. Contract Manufacturing: Partnerships with global pharma companies. Innovation Projects: Focus on R&D for specialty chemicals. Sustainability Initiatives: Green chemistry and eco-friendly production. ⚠️ Risks & Watchpoints Persistent Losses: Despite narrowing, company remains loss-making. Debt Levels: Moderate leverage could pressure balance sheet. Regulatory Risks: Pharma and agrochemical sectors face compliance challenges. Margin Sustainability: Expansion must be sustained across quarters. Global Competition: Intense rivalry in APIs and chemicals. 📑 Social Media–Ready Post 📌 Hikal Q1 FY26 Results Net Loss: ₹74M vs ₹224M (YoY) ⬇️ Revenue: ₹4B vs ₹3.8B (YoY) ⬆️ EBITDA: ₹370M vs ₹251M (YoY) ⬆️ EBITDA Margin: 9.2% vs 6.6% (YoY) ⬆️ 📊 Fundamentals & Ratios Revenue: ~₹15.5B Net Loss: ~₹0.6B Debt-to-Equity: ~0.7 P/E Ratio: Negative ROE: Negative Dividend Yield: Nil 🏦 Projects Pharma API growth Agrochemicals expansion Contract manufacturing partnerships Specialty chemical R&D Sustainability initiatives ⚠️ Risks Persistent losses Debt pressure Regulatory challenges Margin sustainability Global competition

Jeet B Bhayani (SEBI RA)

24 Jul • 10:26 AM · SEBI-Registered Analyst

Hikal Upgrades cGMP Pilot Plant to Boost Pharma R&D Capabilities

Hikal Limited has upgraded its cGMP-compliant pilot plant at its Pune Research & Technology campus, significantly boosting its ability to support global pharmaceutical clients through every stage of drug development. The expanded facility bridges the gap between laboratory research and commercial production, helping companies streamline technology transfers, speed up development timelines, and produce high-quality materials for preclinical and clinical trials while adhering to international regulatory standards. By unifying development and manufacturing at a single campus, the state-of-the-art plant encourages seamless collaboration between scientists and engineers. Equipped with versatile reactors ranging from 20 to 2,000 liters and specialized technology—including cryogenic, hydrogenation, and high-vacuum distillation systems—the facility handles a wide array of complex chemical processes. This investment reinforces Hikal’s standing as a reliable CDMO partner and advances India’s position in the global contract research and life sciences sectors.

HIKAL

Adarsh Nimborkar (SEBI IA)

12 Feb • 9:07 PM · SEBI-Registered Analyst

Hikal Ltd – Stock Overview

HIKAL

Company Profile Hikal Ltd is an Indian pharmaceutical and specialty chemical manufacturing company. It operates in two main segments: pharmaceuticals and crop protection chemicals. The company produces active pharmaceutical ingredients (APIs), intermediates, and specialty chemicals used in medicines and agricultural products. It serves global pharmaceutical and agrochemical companies and exports a significant portion of its production. Business Model Hikal earns revenue by manufacturing and supplying APIs, intermediates and specialty chemicals to large global clients. It also undertakes contract manufacturing and custom synthesis for pharmaceutical and agrochemical companies. Revenue depends on long-term supply contracts, export demand, product pricing and capacity utilisation. The company focuses on niche and complex molecules that offer better margins than commodity chemicals. Industry Position Hikal operates in the specialty chemicals and pharma manufacturing sector. It has established relationships with global clients and benefits from increasing outsourcing by international pharmaceutical and agrochemical companies. However, the industry is competitive and requires strict regulatory compliance and quality standards. Growth is supported by rising demand for specialty chemicals and contract manufacturing. Financial Performance (Broad View) Revenue growth has been moderate in recent years. Profitability has seen pressure due to input cost inflation, demand fluctuations and operational expenses. Margins can vary based on product mix and raw material costs. Overall View Hikal Ltd is a specialty chemical and pharmaceutical manufacturing company with export exposure and niche capabilities. It may suit investors looking for exposure to contract manufacturing and specialty chemicals, but performance depends on global demand, cost control and regulatory compliance.

Rajneesh Sharma CFTe

12 Feb • 1:44 PM · SEBI-Registered Analyst

Hikal Limited (Weekly Chart): Falling Channel Approaching Long-Term Support with RSI Stabilisation

HIKAL

1. Price Structure The stock remains in a broader corrective phase after a prior upcycle, forming lower highs within a descending structure. Recent price action shows a sharp move emerging from the lower end of a falling channel near a historically active demand zone. 2. Trendlines & Structure A long-term declining trendline continues to define overhead resistance, while the current price has been moving inside a short-term falling channel. The latest candle reflects price reacting near the lower boundary of this structure. 3. Key Levels (Chart Observations) Major Support Zone: ₹175–₹208 area acting as a long-term base where price has historically stabilised. Immediate Level: Around ₹215–₹220 where price is currently interacting after the recent move. Overhead Resistance: Descending trendline and prior consolidation band visible in the ₹320–₹360 region. 4. Momentum (RSI) Weekly RSI has been consolidating in the lower range after prolonged weakness. Recent RSI movement shows improvement from oversold territory, indicating stabilising momentum. 5. RSI Structure RSI reflects a bullish divergence pattern where momentum holds relatively steady while price formed lower lows, suggesting internal strength building near support. 6. Volume Behaviour A sharp spike in volume accompanies the latest upward candle, significantly higher than recent averages, highlighting increased participation at lower levels. 7. Overall Observation The chart shows price interacting with a long-term support zone within a broader corrective structure, supported by improving RSI behaviour and elevated volume near the lower boundary. 📢 Disclaimer: For educational and technical analysis purposes only; not investment advice. 👤 Rajneesh Sharma – SEBI Registered Research Analyst (INH000020332)

Hikal Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Hikal Ltd. 👋

Expert Opinions

News & Events

Frequently Asked Questions

What is the share price of Hikal Ltd.?

What is the market cap of Hikal Ltd.?

Should I buy Hikal Ltd. stock now?

What is the 52 week high and low of Hikal Ltd.?

Is the Hikal Ltd. stock good to buy?

Is Hikal Ltd. a good buy for the long term?

Is Hikal Ltd. overvalued or undervalued?

What is the PE and PB ratio of Hikal Ltd.?